

## **SOUTH SUDAN – Pentavalent vaccine support**

This decision letter sets out the programme terms of a programme.

- 1. Country: South Sudan
- 2. Grant number: 1416-SDS-04c-X
- 3. Date of decision letter: 20 November 2015
- 4. Date of the Partnership Framework Agreement: 24 June 2013
- 5. Programme title: New vaccine support (NVS), Pentavalent Routine
- 6. Vaccine type: Pentavalent
- **7.** Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID
- 8. Programme duration<sup>1</sup>: 2014 -2016
- **9. Programme budget (indicative):** (subject to the terms of the partnership framework agreement, if applicable)

	2014-2015	2016	Total <sup>2</sup>
Programme budget (US\$)	US\$4,907,500 <sup>3</sup>	US\$1,804,000	US\$6,711,500

- 10. Vaccine introduction grant (in US\$): Not applicable.
- **11. Indicative annual amounts:** (subject to the terms of the partnership framework agreement, if applicable)<sup>4</sup>

Type of supplies to be purchased	2014-2015	2016
with Gavi funds in each year		
Number of Pentavalent vaccines		956,500
doses		
Number of AD syringes		919,400
Number of safety boxes		10,125
Annual amounts (US\$)	US\$4,907,500 <sup>5</sup>	US\$1,804,000

- **12. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.
- 13. Self-procurement: Not applicable.

2 Chemin des Mines 1202 Geneva. Switzerland Tel. + 41 22 909 65 00 Fax + 41 22 909 65 50 www.gavi.org info@gavi.org

<sup>&</sup>lt;sup>1</sup> This is the entire duration of the programme.

<sup>&</sup>lt;sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>&</sup>lt;sup>3</sup> This is the consolidated amount for all previous years.

<sup>&</sup>lt;sup>4</sup> This is the amount that Gavi has approved.

<sup>&</sup>lt;sup>5</sup> This is the consolidated amount for all previously approved years.



14. Co-financing obligations: Reference code: 1416-SDS-04c-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased	2016
with Country funds in each year	
Number of vaccine doses	137,000
Value of vaccine doses (US\$)	US\$246,091
Total co-financing payments (US\$)	US\$252,000
(including freight)	

- 15. Operational support for campaigns: Not applicable
- **16. Additional reporting requirements:** The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

	5
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall	To be agreed
report on programmatic and financial performance.	with Secretariat

- 17. Financial clarifications: Not applicable.
- 18. Other conditions: Not applicable.

On behalf of Gavi

Hind Khatib-Othman Managing Director, Country Programmes

blist . Ho bilt

20 November 2015